SOURCE: Equity News Circuit

Equity News Circuit

April 22, 2013 08:15 ET

Free Research Reports on AMD, MSFT, PRGX and VRTX Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit

NEW YORK, NY--(Marketwired - Apr 22, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Advanced Micro Devices, Inc. (NYSE: AMD) shares declined 1.59 percent on volume of over 25.0 million shares traded Friday to close at $2.47 a share. The company reported revenues of $1.09 billion for the first quarter of 2013, a decrease of 6 percent sequentially and 31 percent year-over-year.

Find out more about Advanced Micro Devices including full access to the free equity report at: www.BedfordReport.com/AMD

Microsoft Corporation (NASDAQ: MSFT) shares spiked 3.39 percent on volume of nearly 100.0 million shares traded Friday to close at $29.76. The company reported revenues of $20.49 billion for the third quarter of fiscal 2013, an increase of 18 percent when compared to the year ago quarter.

Find out more about Microsoft including full access to the free equity report at: www.BedfordReport.com/MSFT

PRGX Global Inc. (NASDAQ: PRGX) shares fell 15.97 percent on volume of 1.37 million shares traded Friday to close at $5.24 a share. The company has announced that revenue for the first quarter is expected to be 12% to 14% lower than revenue in the first quarter of 2012.

Find out more about PRGX Global including full access to the free equity report at: www.BedfordReport.com/PRGX

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares surged 61.91 percent on volume of nearly 25.0 million shares traded Friday to close at $85.60 a share. The company announced data from a Phase 2 study of VX-661 and ivacaftor showed "statistically significant improvements in lung function in people with cystic fibrosis who have two copies of the F508del mutation."

Find out more about Vertex Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/VRTX

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information